All Episodes
Biotech Blueprint — 42 episodes
FDA Shifts to One Pivotal Trial and Moderna Flu Shot Back Under FDA Review – This Week in Biotech #90
Hims Launches Compounded GLP-1 Pill, CVS Forces Biosimilars – This Week in Biotech #88
Regenxbio FDA Hold, Sanofi Vaccine Demand Softness, and CMS Negotiation Expansion – This Week in Biotech #87
Moderna Merck V940 Shows Five Year Melanoma Durability, Biopharma Deal Activity Picks Up
#CDC #Vaccine Schedule Shifts, Practice-Changing Phase 3 Wins, and Deal Heat – This Week in Biotech #84
Inside NImmune’s Phase 3 Push in Ulcerative Colitis
FDA Tightens Vaccine Pathways, Medicare Slashes Drug Prices — This Week in Biotech #80
CDC’s Autism Reversal Shocks Experts, mRNA Flu Shot Advances, Big Oncology Wins - This Week in Biotech #79
FDA Opens New Pathway, Pfizer’s $10B GLP-1 Win, and Biotech’s Return to Offense — This Week in Biotech #78
Inside Sensible Biotechnologies: Reinventing mRNA Manufacturing
Trump Reshapes Obesity Drug Prices, Novo Tops Pfizer Again — This Week in Biotech #77
Novo tops Pfizer’s obesity bid; FDA moves to speed biosimilar approvals; Moderna–Merck rumors build — This Week in Biotech #76
Drug launch prices soar; mRNA shots linked to longer cancer survival — This Week in Biotech #75
How mRNA Could Defeat Latent Viruses and Train Immunity Against Cancer
Trump cuts IVF & Medicaid drug prices; Novo buys Omeros; Lilly's GLP-1 orforglipron shines — This Week in Biotech #74
Pharma Tariffs on Ice, FDA Limits Filings, Amgen’s PCSK9 Win — This Week in Biotech #72 Pharma Tariffs on Ice, FDA Limits Filings, Amgen’s PCSK9 Win — This Week in Biotech #72
ACIP votes, Roche-89bio deal, Regeneron’s FOP win — This Week in Biotech #70
The mRNA Revolution: Beyond COVID to Cancer, Flu and Herpes Vaccines
Novo’s Layoffs, Novartis’ $1.4B Buy, Pancreatic Cancer Progress — This Week in Biotech #69
Ionis' Olezarsen Win, Novartis Licenses Arrowhead, CDC Vaccine Fight — This Week in Biotech #68
Monarez Fired, Novo’s srRNA Deal, ImmunityBio Wows in GBM — This Week in Biotech #67
Viking Falls on Obesity Pill, Rocket’s Gene Therapy Resumes, FDA Greenlights Papzimeos — This Week in Biotech #66
Lilly Bets on AI, Prasad Returns, and Brinsupri Breaks Through - This Week in Biotech #65
RFK Jr. Ends mRNA Funding, Sarepta Beats Q2, and Eli Lilly Falls — This Week in Biotech #64
FDA Shake Up, Sarepta Rebounds, and Trump Targets Drug Prices — This Week in #Biotech 63
Sarepta, Elevidys, and the Future of AAV Gene Therapy
Sarepta’s Gene Therapy Crisis Deepens — This Week in Biotech #62
Sarepta’s $400M Pivot, MiNK’s 500% Surge, and AML Breakthroughs — This Week in Biotech #61
CRISPR in 2025: Clinical Use, Regulatory Pressure, and Future Promise
KalVista’s FDA Win, Merck’s $10B Deal, and CRISPR Momentum — Biotech #60
Sparks Fly in Biotech — This Week in Biotech #59
FDA Drama & Psychedelic Setback — This Week in Biotech #58
HIV Breakthrough & Gene Editing Deals — This Week in Biotech #57
Biotech Caught Between AI Momentum and Political Turbulence — This Week in Biotech #56
Navigating Biotech Jobs in 2025: AI, Networking, and Career Strategy
ASCO Breakthroughs, Gene Therapy Stumbles, and Omada's IPO debut — This Week in Biotech #55
CRISPR Setbacks, Vaccine Policy Reversed, and an Oral Antibiotic Breakthrough — This Week in Biotech #54
Organoids, AI, and the FDA’s Move Away from Animal Models
Tighter Boosters, Novavax's Win, and Psychedelic Signals — This Week in Biotech #53
Medicare Benchmarking, Novo's Transition, and Biohaven's Setback — This Week in Biotech #52
CRISPR, Prasad, and the NIH budget bomb — This Week in Biotech #51
From Wall Street to Wet Lab: Mapping the Future of Biotech